Managed by experienced biotech industry leaders focused on developing novel biological therapies to address unmet clinical needs.
Targeting critical pathways in clinical and preclinical stages to protect biological structures and restore organ function.
Developing selective inhibitors designed to block caspase activation, key mediators of cell death and chronic inflammation.
Utilizing unique hypoxic cell technologies to produce matrix materials and growth factors that stimulate natural healing.
Pioneering therapies aimed at broad clinical applications across infectious, inflammatory, and orthopedic conditions.
Our drug development candidate portfolio targeting significant patient needs.
| Candidate / Target | Indication | Discovery | Phase 1 | Phase 2 | Status |
|---|---|---|---|---|---|
| EMRICASAN (Pan-Caspase) | Infectious Diseases / COVID-19 | ✓ | ✓ | ✓ | Phase 1/2 Active |
| CTS-2017 (Caspase-1) | Inflammatory Conditions | ✓ | ✓ | — | Preclinical / Phase 1 |
| HST-003 (hECM) | Joint Cartilage Repair | ✓ | ✓ | ✓ | Phase 1/2 Clinical |
Interested in learning more about Histogen's executive leadership, scientific platform, and corporate background?
Read Our Full About Us Story